Cancer Prevention Pharmaceuticals Inc logo

CPP - Cancer Prevention Pharmaceuticals Inc Share Price

n/a 0.0  0.0%

Last Trade -

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £3.71m
Position in Universe th / 6344
Bullish
Bearish
Unlock CPP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 2016E 2017E CAGR / Avg
0.000 0.000 0.000 0.10 0.48 3.71 +506.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2016, Cancer Prevention Pharmaceuticals Inc revenues increased from $121K to $1M. Net loss increased 65% to $3.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 73% to $2.2M (expense), General and administrative increase from $356K to $966K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CPP Revenue Unlock CPP Revenue

Net Income

CPP Net Income Unlock CPP Revenue

Normalised EPS

CPP Normalised EPS Unlock CPP Revenue

PE Ratio Range

CPP PE Ratio Range Unlock CPP Revenue

Dividend Yield Range

CPP Dividend Yield Range Unlock CPP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CPP EPS Forecasts Unlock CPP Revenue
Profile Summary

Cancer Prevention Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. Its investigational drug product, CPP-1X/sul, is a combination of the polyamine synthesis inhibitor CPP-1X and the non-steroidal anti-inflammatory drug sulindac. Its product pipeline includes CPP-1X/sul and CPP-1X. It is engaged in enrolling patients in its Phase III clinical trial with its product candidate, CPP-1X/sul, for the treatment of familial adenomatous polyposis (FAP). CPP-1X/sul, which is used for treating colon cancer risk reduction, is in Phase III clinical trial. It has completed Phase I clinical trial for CPP-1X in treating gastric cancer. CPP-1X is in Phase II clinical trial for the treatment of neuroblastoma, and in Phase I clinical trial for the treatment of early onset type 1 diabetes.

Directors
Last Annual December 31st, 2015
Last Interim March 31st, 2016
Incorporated December 22, 2009
No. of Shareholders: n/a
No. of Employees: 10
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NYSE MKT (Dual Listing)
Shares in Issue 6,759,443
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CPP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CPP
Upcoming Events for CPP
Frequently Asked Questions for Cancer Prevention Pharmaceuticals Inc
What is the Cancer Prevention Pharmaceuticals Inc share price?

As of , shares in Cancer Prevention Pharmaceuticals Inc are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Cancer Prevention Pharmaceuticals Inc share price performed this year?

Shares in Cancer Prevention Pharmaceuticals Inc are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cancer Prevention Pharmaceuticals Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Cancer Prevention Pharmaceuticals Inc?

There are no analysts currently covering Cancer Prevention Pharmaceuticals Inc.

When will Cancer Prevention Pharmaceuticals Inc next release its financial results?

Cancer Prevention Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2017-03-31
What is the Cancer Prevention Pharmaceuticals Inc dividend yield?

Cancer Prevention Pharmaceuticals Inc does not currently pay a dividend.

Does Cancer Prevention Pharmaceuticals Inc pay a dividend?

Cancer Prevention Pharmaceuticals Inc does not currently pay a dividend.

When does Cancer Prevention Pharmaceuticals Inc next pay dividends?

Cancer Prevention Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Cancer Prevention Pharmaceuticals Inc shares?

To buy shares in Cancer Prevention Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cancer Prevention Pharmaceuticals Inc?

Shares in Cancer Prevention Pharmaceuticals Inc are currently trading at n/a, giving the company a market capitalisation of £n/a.

Where are Cancer Prevention Pharmaceuticals Inc shares listed? Where are Cancer Prevention Pharmaceuticals Inc shares listed?

Here are the trading details for Cancer Prevention Pharmaceuticals Inc:

Country of listing: United States
Exchange: ASQ
Ticker Symbol: CPP
What kind of share is Cancer Prevention Pharmaceuticals Inc?

We were not able to load our ranking data for Cancer Prevention Pharmaceuticals Inc

Is there a Cancer Prevention Pharmaceuticals Inc share price forecast 2020?

We were not able to load any forecast data for Cancer Prevention Pharmaceuticals Inc.

How can I tell whether the Cancer Prevention Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cancer Prevention Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Cancer Prevention Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cancer Prevention Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Cancer Prevention Pharmaceuticals Inc.

Who are the key directors of Cancer Prevention Pharmaceuticals Inc?

Cancer Prevention Pharmaceuticals Inc's management team is headed by:

Jeffrey Jacob - CHM
Eugene Gerner - FDR
Christopher Richied - CFO
Daniel Donovan - DRC
Richard Love - IND
Jon Saxe - IND
Who are the major shareholders of Cancer Prevention Pharmaceuticals Inc?

Here are the top five shareholders of Cancer Prevention Pharmaceuticals Inc based on the size of their shareholding:

Similar to CPP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.